RU2020111554A - Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген - Google Patents
Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген Download PDFInfo
- Publication number
- RU2020111554A RU2020111554A RU2020111554A RU2020111554A RU2020111554A RU 2020111554 A RU2020111554 A RU 2020111554A RU 2020111554 A RU2020111554 A RU 2020111554A RU 2020111554 A RU2020111554 A RU 2020111554A RU 2020111554 A RU2020111554 A RU 2020111554A
- Authority
- RU
- Russia
- Prior art keywords
- antigen binding
- seq
- chain variable
- variable domain
- amino acid
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims 194
- 102000036639 antigens Human genes 0.000 title claims 194
- 108091007433 antigens Proteins 0.000 title claims 194
- 102000004169 proteins and genes Human genes 0.000 title claims 95
- 108090000623 proteins and genes Proteins 0.000 title claims 95
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 title claims 19
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 title claims 19
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 title claims 19
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 title claims 11
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 title claims 11
- 206010028980 Neoplasm Diseases 0.000 title claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 116
- 239000012634 fragment Substances 0.000 claims 13
- 101150013553 CD40 gene Proteins 0.000 claims 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 6
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 6
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 6
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 6
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 6
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 102100032912 CD44 antigen Human genes 0.000 claims 4
- 102100025221 CD70 antigen Human genes 0.000 claims 4
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 4
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 4
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 4
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 4
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 102100029198 SLAM family member 7 Human genes 0.000 claims 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 3
- 102100022749 Aminopeptidase N Human genes 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 102100027221 CD81 antigen Human genes 0.000 claims 3
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims 3
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 3
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 3
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 3
- 101000984198 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 1 Proteins 0.000 claims 3
- 101000984197 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 claims 3
- 101000984200 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 3 Proteins 0.000 claims 3
- 101000984199 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 4 Proteins 0.000 claims 3
- 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 claims 3
- 101000984206 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 6 Proteins 0.000 claims 3
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims 3
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 claims 3
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 claims 3
- 101000984185 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 5 Proteins 0.000 claims 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 3
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 3
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 claims 3
- 102100025587 Leukocyte immunoglobulin-like receptor subfamily A member 1 Human genes 0.000 claims 3
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 claims 3
- 102100025556 Leukocyte immunoglobulin-like receptor subfamily A member 3 Human genes 0.000 claims 3
- 102100025555 Leukocyte immunoglobulin-like receptor subfamily A member 4 Human genes 0.000 claims 3
- 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 claims 3
- 102100025553 Leukocyte immunoglobulin-like receptor subfamily A member 6 Human genes 0.000 claims 3
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims 3
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims 3
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 claims 3
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 claims 3
- 102100025577 Leukocyte immunoglobulin-like receptor subfamily B member 5 Human genes 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 3
- 102100035721 Syndecan-1 Human genes 0.000 claims 3
- 102100026967 T cell receptor beta chain MC.7.G5 Human genes 0.000 claims 3
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 101710147153 T-cell receptor beta-1 chain C region Proteins 0.000 claims 3
- 101710091597 T-cell receptor beta-2 chain C region Proteins 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- -1 VLA4 Proteins 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100025626 GTP-binding protein GEM Human genes 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000856606 Homo sapiens GTP-binding protein GEM Proteins 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000001608 potassium adipate Substances 0.000 claims 1
- 239000001601 sodium adipate Substances 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549201P | 2017-08-23 | 2017-08-23 | |
| US62/549,201 | 2017-08-23 | ||
| US201762558514P | 2017-09-14 | 2017-09-14 | |
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US201762558509P | 2017-09-14 | 2017-09-14 | |
| US201762558511P | 2017-09-14 | 2017-09-14 | |
| US62/558,514 | 2017-09-14 | ||
| US62/558,510 | 2017-09-14 | ||
| US62/558,511 | 2017-09-14 | ||
| US62/558,509 | 2017-09-14 | ||
| US201762566828P | 2017-10-02 | 2017-10-02 | |
| US62/566,828 | 2017-10-02 | ||
| US201762581357P | 2017-11-03 | 2017-11-03 | |
| US62/581,357 | 2017-11-03 | ||
| US201762608384P | 2017-12-20 | 2017-12-20 | |
| US62/608,384 | 2017-12-20 | ||
| PCT/US2018/047714 WO2019040727A1 (en) | 2017-08-23 | 2018-08-23 | BINDING PROTEINS FOR NKG2D, CD16 AND ANTIGEN ASSOCIATED WITH A TUMOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020111554A true RU2020111554A (ru) | 2021-09-23 |
| RU2020111554A3 RU2020111554A3 (enExample) | 2022-01-19 |
Family
ID=65439284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020111554A RU2020111554A (ru) | 2017-08-23 | 2018-08-23 | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200231679A1 (enExample) |
| EP (1) | EP3672993A4 (enExample) |
| JP (2) | JP2020531525A (enExample) |
| KR (1) | KR20200038530A (enExample) |
| CN (1) | CN111315778A (enExample) |
| AU (1) | AU2018322178A1 (enExample) |
| BR (1) | BR112020003654A2 (enExample) |
| CA (1) | CA3072919A1 (enExample) |
| IL (2) | IL311488A (enExample) |
| MX (1) | MX2020002036A (enExample) |
| RU (1) | RU2020111554A (enExample) |
| SG (1) | SG11201913968VA (enExample) |
| WO (1) | WO2019040727A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| CN115298217A (zh) * | 2019-10-15 | 2022-11-04 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16及flt3的蛋白质 |
| US20230073946A1 (en) * | 2020-01-20 | 2023-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Affinity peptide conjugated with antioxidant for protection of proteins from oxidation |
| MX2022013944A (es) * | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| CN114437214B (zh) * | 2020-11-03 | 2023-06-02 | 南京北恒生物科技有限公司 | 靶向lir1的抗体及其用途 |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| WO2025166146A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + ox40 targeting antibodies and uses thereof |
| WO2025166138A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + tslp targeting antibodies and uses thereof |
| CN118812708B (zh) * | 2024-06-28 | 2025-04-04 | 北京普利米特生物科技有限公司 | 抗il-33抗体或其抗原结合片段及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1266014A2 (en) * | 2000-03-24 | 2002-12-18 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US20070071759A1 (en) * | 2005-06-29 | 2007-03-29 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| KR101615935B1 (ko) * | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP3587448B1 (en) * | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| EP3241561B1 (en) * | 2014-03-05 | 2025-04-30 | Autolus Limited | Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2 |
| JP2018503399A (ja) * | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| AU2016219785B2 (en) * | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| US20200048345A1 (en) * | 2015-12-28 | 2020-02-13 | Innate Pharma | Multispecific antigen binding proteins |
| CA3011535A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
-
2018
- 2018-08-23 MX MX2020002036A patent/MX2020002036A/es unknown
- 2018-08-23 RU RU2020111554A patent/RU2020111554A/ru unknown
- 2018-08-23 JP JP2020511319A patent/JP2020531525A/ja not_active Ceased
- 2018-08-23 US US16/639,150 patent/US20200231679A1/en not_active Abandoned
- 2018-08-23 WO PCT/US2018/047714 patent/WO2019040727A1/en not_active Ceased
- 2018-08-23 SG SG11201913968VA patent/SG11201913968VA/en unknown
- 2018-08-23 CN CN201880054953.2A patent/CN111315778A/zh active Pending
- 2018-08-23 AU AU2018322178A patent/AU2018322178A1/en not_active Abandoned
- 2018-08-23 KR KR1020207007908A patent/KR20200038530A/ko not_active Ceased
- 2018-08-23 IL IL311488A patent/IL311488A/en unknown
- 2018-08-23 CA CA3072919A patent/CA3072919A1/en active Pending
- 2018-08-23 EP EP18848423.2A patent/EP3672993A4/en not_active Withdrawn
- 2018-08-23 BR BR112020003654-4A patent/BR112020003654A2/pt not_active IP Right Cessation
-
2020
- 2020-02-16 IL IL272706A patent/IL272706A/en unknown
-
2023
- 2023-02-24 JP JP2023027219A patent/JP2023062184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200231679A1 (en) | 2020-07-23 |
| IL272706A (en) | 2020-04-30 |
| EP3672993A1 (en) | 2020-07-01 |
| CN111315778A (zh) | 2020-06-19 |
| CA3072919A1 (en) | 2019-02-28 |
| SG11201913968VA (en) | 2020-01-30 |
| JP2023062184A (ja) | 2023-05-02 |
| BR112020003654A2 (pt) | 2020-11-17 |
| AU2018322178A1 (en) | 2020-02-20 |
| IL311488A (en) | 2024-05-01 |
| WO2019040727A1 (en) | 2019-02-28 |
| JP2020531525A (ja) | 2020-11-05 |
| MX2020002036A (es) | 2020-03-24 |
| KR20200038530A (ko) | 2020-04-13 |
| RU2020111554A3 (enExample) | 2022-01-19 |
| EP3672993A4 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020111554A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2020531525A5 (enExample) | ||
| JP7550591B2 (ja) | 多重特異的ＮＫｐ４６結合タンパク質 | |
| Hosseini et al. | Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials | |
| JP6840682B2 (ja) | 多重特異的抗原結合タンパク質 | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| US20220135676A1 (en) | Multispecific antigen binding proteins | |
| US20210024630A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2020522473A5 (enExample) | ||
| WO2015197582A1 (en) | Monomeric multispecific antigen binding proteins | |
| RU2021121771A (ru) | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19 | |
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| US20200325232A1 (en) | Multispecific antigen binding proteins | |
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 | |
| Dhimolea et al. | World bispecific antibody summit, September 27–28, 2011, Boston, MA | |
| Lutz et al. | Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells | |
| JP2023524238A (ja) | 治療用ＳＩＲＰα抗体 | |
| Dickopf et al. | Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi-or multispecific antibodies | |
| Schubert et al. | A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells | |
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| US20240400718A1 (en) | ANTIBODY BINDING TO LINKER OF scFv OR LIKE | |
| RU2020114236A (ru) | Новые биспецифичные полипептидные комплексы против cd3/cd19 | |
| RU2021114765A (ru) | Антитела, содержащие только тяжелые цепи, которые связываются с cd38 |